Project Grant R01HL178074
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $594,547 to Harvard Medical School to conduct research on the regulation of arousal and sleep quality. The project aims to characterize a gut-to-brain signaling pathway that uses information about ingested nutrients to control arousal levels and sleep depth, without affecting overall sleep duration. The research will investigate...
- This $438,915 project grant was awarded by the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training federal grant program (CFDA 93.859), to Florida State University (FSU). The overarching goal of this 5-year project is to advance scientific understanding of the genetic and molecular basis of circadian rhythms and sleep disorders in mammalian models and humans. Specifically, the research aims to: 1) Identify and characterize the genetic...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), is focused on assessing whether genetic risk variants for Alzheimer's disease (AD) have a pleiotropic effect on sleep. The primary objectives are to conduct in silico variant-to-gene mapping analysis to identify potential shared genetic factors underlying AD and sleep phenotypes, and to use CRISPR in zebrafish models to directly evaluate the impact of putative AD...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $134,982 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the genetic and nutritional control of sleep across seasons. The overarching goal is to investigate how the circadian clock and seasonal variations in light and nutrients impact sleep and feeding behaviors. Key activities include analyzing sleep, feeding,...
- This $782,473 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to improve understanding of the pathogenesis of sleep apnea using novel imaging techniques during sleep. The project aims to characterize the site and pattern of airway collapse as well as how upper airway anatomy mediates this collapse, which could provide new insights to guide optimal therapies, particularly for patients who cannot tolerate...
- This Project Grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund research into the molecular interplay of sleep and neurodegeneration using the Drosophila model system. With $2.14 million provided over 11 months, the Trustees of the University of Pennsylvania will investigate how expression of the TDP-43 protein linked to neurodegenerative diseases disrupts sleep in fruit flies. Researchers will aim to define the specific glial subtypes...
- This federal Project Grant award, totaling $1,621,874.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) with an award date of Sep 23, 2025 and an ultimate completion date of Jun 30, 2027. The award was granted to Brigham & Women's Hospital Inc., a subsidiary of the larger Partners Healthcare System (now Mass General Brigham), to conduct research on the role of ambient lighting in circadian misalignment and its...
- This Project Grant award for $730,993.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanisms by which internal circadian misalignment contributes to the cardiometabolic risk associated with sleep loss. The project aims to determine if preventing light exposure and food intake during the circadian biological night can mitigate the adverse cardiometabolic effects of insufficient sleep. Researchers at...
- This federal Project Grant award was provided by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), to the University of Utah. The $458,452 grant, awarded on June 1, 2025, will support a research project titled "Mechanisms of Psychostimulant-Sleep Interactions" over a 5-year period ending on February 28, 2030. The key objective of this research project is to identify genes and molecular mechanisms that impact...
- This federal Project Grant award of $125,000.00, provided by the National Institute on Aging (CFDA 93.866 Aging Research), supports research to investigate the relationship between sleep loss and neurodegeneration. The grantee, The Washington University, will use the funding to examine how sleep deprivation can epigenetically alter microglial responses to tau protein aggregates, which is a key pathological feature of Alzheimer's disease and other tauopathies. The research aims to identify...
This federal Project Grant award, valued at $755,257.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award aims to study the role of GPI-anchor biosynthesis in regulating sleep, with the goal of improving understanding of the genetic factors underlying sleep disorders such as insomnia. The research will be conducted by Texas A&M University and will involve a multi-pronged approach, including genomic, computational, and behavioral analyses. Key objectives include identifying targets of the GPI-anchor biosynthesis pathway in fruit flies and elucidating the underlying mechanism of their impact on sleep centers in the brain. The researchers will also apply variant-to-gene mapping in human progenitor cells to understand how genetic variation associated with sleep-regulating genes affects their function. Additionally, the project will characterize the impact of variation in insomnia risk genes through in-depth human phenotyping of individuals harboring rare variants with predicted loss of function. The award has a period of performance from September 11, 2025 to June 30, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $755.3k | 9/11/25 |